Drug General Information (ID: DDIF61D94K)
Drug Name			Escitalopram		Drug Info		Inotuzumab ozogamicin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antidepressants				Antineoplastics

Mechanism of Escitalopram-Inotuzumab ozogamicin Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Escitalopram				Inotuzumab ozogamicin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Escitalopram and Inotuzumab ozogamicin

Recommended Action
Management		Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References
1	Canadian Pharmacists Association.
2	Castro VM, Clements CC, Murphy SN, et al. "QT interval and antidepressant use: a cross sectional study of electronic health records." BMJ 346 (2013): f288. [PMID: 23360890]
3	Cerner Multum, Inc. "Australian Product Information.".
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Do A, Noohi S, Elie D, et al. Health Canada Warning on Citalopram and Escitalopram--Its Effects on Prescribing in Consultation-Liaison Psychiatry.?Psychosomatics. 2016;57(1):57-63. [PMID: 26633294]
6	Product Information. Lexapro (escitalopram). Forest Pharmaceuticals, St. Louis, MO.
7	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".